摘要
目的 探讨CA12 5对妇科肿瘤诊断及疗效监测的临床应用价值。方法 应用放射免疫法 (IR MA)测定 131例妇科恶性肿瘤、90例妇科良性肿瘤患者、82例健康妇女血清CA12 5水平。结果 131例妇科恶性肿瘤患者血清CA12 5水平为 182 .5± 16 1.2U ml,检测阳性率为 80 .2 % ,90例良性肿瘤患者血清CA12 5水平为 2 8.2± 2 6 .0U ml,检测阳性率为 2 1.1% ,两者相比差异有显著性 (P <0 .0 1)。 82例健康妇女血清CA12 5水平为 18.5± 8.3U ml,随访 19例妇科恶性肿瘤患者治疗前CA12 5水平为 380 .2± 16 0 .5U ml,治疗后CA12 5水平为 2 4 .0± 2 0 .5U ml,两者相比亦有显著性差异 (P <0 .0 1)。结论 CA12 5可作为妇科肿瘤诊断及良恶性肿瘤鉴别的指标 ,并可进行疗效观察及监测复发。
Objective To study clinical significance of CA125 in patients with gynecologic tumors.Methods Serum CA125 was determined in 131 cases of gynecologic malignant tumors,90 cases of benign tumors and 82 cases of healthy woman by IRMA.Results There were 182.5±161.2 U/ml of serum CA125 with 80.2% postive in 131 cases of gynecologic malignant tumors and 28.2±26.0 U/ml with 21.1% positive in 90 cases of benign tumors. The statistic significance can be seen between malignant and benign tumors(P<0.01).There were 18.5±8.3 U/ml in 82 cases of healthy women and 380.2±160.5 U/ml before curing and 44.5±30.4 U/ml after curing in 19 cases of malignant tumors. There was statistic significance between before and after curing (P<0.01). Conclusion CA125 is a good tumor mark in diagnosing gynecologic tumors.
出处
《陕西肿瘤医学》
2002年第3期171-172,共2页
ShanXi Oncology Medicine
